Morepen Laboratories Gestion

Gestion contrôle des critères 3/4

Le PDG Morepen Laboratories est Sushil Suri, nommé en Oct2000, a un mandat de 24.08 ans. détient directement 1.22% des actions de la société, d'une valeur de ₹ 496.16M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 7.9 ans et 4.8 ans.

Informations clés

Sushil Suri

Directeur général

₹39.1m

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	24.1yrs
Propriété du PDG	1.2%
Durée moyenne d'occupation des postes de direction	7.9yrs
Durée moyenne du mandat des membres du conseil d'administration	4.8yrs

Mises à jour récentes de la gestion

Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)

Sep 22

Recent updates

There's Reason For Concern Over Morepen Laboratories Limited's (NSE:MOREPENLAB) Massive 30% Price Jump

Aug 20

Impressive Earnings May Not Tell The Whole Story For Morepen Laboratories (NSE:MOREPENLAB)

Aug 09

Improved Earnings Required Before Morepen Laboratories Limited (NSE:MOREPENLAB) Stock's 29% Jump Looks Justified

Jul 05

Does Morepen Laboratories (NSE:MOREPENLAB) Have A Healthy Balance Sheet?

Jun 13

Morepen Laboratories Limited's (NSE:MOREPENLAB) Popularity With Investors Is Under Threat From Overpricing

Apr 23

Morepen Laboratories (NSE:MOREPENLAB) Seems To Use Debt Quite Sensibly

Nov 23

Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)

Sep 22

Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?

Aug 10

Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)

Sep 21

Should You Be Adding Morepen Laboratories (NSE:MOREPENLAB) To Your Watchlist Today?

Apr 05

Is Morepen Laboratories Limited's (NSE:MOREPENLAB) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Feb 07

Morepen Laboratories (NSE:MOREPENLAB) Shareholders Have Enjoyed A 91% Share Price Gain

Jan 21

Morepen Laboratories (NSE:MOREPENLAB) Has A Pretty Healthy Balance Sheet

Jan 03

Is There More To The Story Than Morepen Laboratories's (NSE:MOREPENLAB) Earnings Growth?

Dec 16

Should You Be Adding Morepen Laboratories (NSE:MOREPENLAB) To Your Watchlist Today?

Nov 28

Analyse de la rémunération des PDG

Comment la rémunération de Sushil Suri a-t-elle évolué par rapport aux bénéfices de Morepen Laboratories?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	₹1b
Jun 30 2024	n/a	n/a	₹1b
Mar 31 2024	₹39m	n/a	₹962m
Dec 31 2023	n/a	n/a	₹761m
Sep 30 2023	n/a	n/a	₹531m
Jun 30 2023	n/a	n/a	₹477m
Mar 31 2023	₹48m	₹44m	₹387m
Dec 31 2022	n/a	n/a	₹428m
Sep 30 2022	n/a	n/a	₹553m
Jun 30 2022	n/a	n/a	₹768m
Mar 31 2022	₹91m	₹87m	₹1b
Dec 31 2021	n/a	n/a	₹1b
Sep 30 2021	n/a	n/a	₹1b
Jun 30 2021	n/a	n/a	₹1b
Mar 31 2021	₹54m	₹51m	₹971m
Dec 31 2020	n/a	n/a	₹814m
Sep 30 2020	n/a	n/a	₹684m
Jun 30 2020	n/a	n/a	₹453m
Mar 31 2020	₹17m	₹16m	₹336m
Dec 31 2019	n/a	n/a	₹331m
Sep 30 2019	n/a	n/a	₹312m
Jun 30 2019	n/a	n/a	₹340m
Mar 31 2019	₹12m	₹11m	₹288m
Dec 31 2018	n/a	n/a	₹252m
Sep 30 2018	n/a	n/a	₹267m
Jun 30 2018	n/a	n/a	₹308m
Mar 31 2018	₹6m	₹4m	₹296m

Rémunération vs marché: La rémunération totale de Sushil ($USD 464.10K ) est supérieure à la moyenne des entreprises de taille similaire sur le marché Indian ($USD 271.25K ).

Rémunération et revenus: La rémunération de Sushil a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Sushil Suri (60 yo)

24.1yrs

Titularisation

₹39,112,000

Compensation

Mr. Sushil Suri, B.Sc., FCA has been Managing Director of Morepen Laboratories Limited since October 2000. He has been Chairman of Morepen Laboratories Limited since October 2000 and has been its Director...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Sushil Suri	Chairman & MD	24.1yrs	₹39.11m	1.22% ₹ 496.2m
Sanjay Suri	Whole-Time Director	9.8yrs	₹21.80m	1.01% ₹ 408.4m
Ajay Sharma	Chief Financial Officer	10.3yrs	₹9.80m	pas de données
Bhola Prasad	General Manager of Process Engineering & Technology Transfer	no data	pas de données	pas de données
Sunita Suri	Manager of Administration	no data	pas de données	0.58% ₹ 236.3m
Vipul Srivastava	Company Secretary & Compliance Officer	6yrs	₹1.84m	pas de données
Vikas Sharma	Functional Head of Talent Acquisition & HRBP	less than a year	pas de données	pas de données
Amita Sharma	Chief Operating Officer of API	less than a year	pas de données	pas de données
Anubhav Suri	Head of Medipath Division	no data	pas de données	0.42% ₹ 168.9m
Kushal Suri	Head of International Business Development	no data	pas de données	pas de données
Varun Suri	Chief Executive Officer of Consumer Division	no data	pas de données	0.56% ₹ 225.9m
H. Manjunath	Chief of R&D	no data	pas de données	pas de données

7.9yrs

Durée moyenne de l'emploi

47.5yo

Âge moyen

Gestion expérimentée: L'équipe dirigeante de MOREPENLAB est chevronnée et expérimentée (7.9 années d'ancienneté moyenne).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Sushil Suri	Chairman & MD	32.8yrs	₹39.11m	1.22% ₹ 496.2m
Sanjay Suri	Whole-Time Director	5.3yrs	₹21.80m	1.01% ₹ 408.4m
Sharad Jain	Independent Director	less than a year	pas de données	pas de données
Praveen Dutt	Independent Director	5.3yrs	₹520.00k	pas de données
- Savita	Independent Director	4.4yrs	₹300.00k	pas de données
Ranjit Khattar	Independent Director	less than a year	pas de données	pas de données

4.8yrs

Durée moyenne de l'emploi

56yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de MOREPENLAB sont considérés comme expérimentés (ancienneté moyenne 4.8 ans).

Morepen Laboratories Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Morepen Laboratories Limited Announces Board Cessation

Morepen Laboratories Limited, Annual General Meeting, Sep 28, 2024

Morepen Laboratories Limited, Annual General Meeting, Sep 28, 2024

Morepen Laboratories Limited Announces the Promotion of Amita Sharma to Chief Operating Officer -API

Morepen Laboratories Limited Announces Resignation of Rolli Saxena, General Manager - HR, Being A Functional Head and Senior Management Personnel

Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)

Recent updates

Second quarter 2025 earnings released: EPS: ₹0.65 (vs ₹0.42 in 2Q 2024)

Morepen Laboratories Limited to Report Q2, 2025 Results on Nov 11, 2024

Morepen Laboratories Limited Announces Board Cessation

Morepen Laboratories Limited, Annual General Meeting, Sep 28, 2024

Investor sentiment improves as stock rises 21%

Morepen Laboratories Limited, Annual General Meeting, Sep 28, 2024

There's Reason For Concern Over Morepen Laboratories Limited's (NSE:MOREPENLAB) Massive 30% Price Jump

Investor sentiment improves as stock rises 19%

Impressive Earnings May Not Tell The Whole Story For Morepen Laboratories (NSE:MOREPENLAB)

Morepen Laboratories Limited to Report Q1, 2025 Results on Aug 12, 2024

New minor risk - Shareholder dilution

Full year 2024 earnings released: EPS: ₹1.88 (vs ₹0.77 in FY 2023)

Morepen Laboratories Limited has filed a Follow-on Equity Offering.

Improved Earnings Required Before Morepen Laboratories Limited (NSE:MOREPENLAB) Stock's 29% Jump Looks Justified

Does Morepen Laboratories (NSE:MOREPENLAB) Have A Healthy Balance Sheet?

Investor sentiment improves as stock rises 17%

Full year 2024 earnings released: EPS: ₹1.88 (vs ₹0.77 in FY 2023)

Morepen Laboratories Limited to Report Q4, 2024 Results on May 21, 2024

Morepen Laboratories Limited's (NSE:MOREPENLAB) Popularity With Investors Is Under Threat From Overpricing

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 15%

Investor sentiment deteriorates as stock falls 15%

Morepen Laboratories Limited Announces the Promotion of Amita Sharma to Chief Operating Officer -API

Third quarter 2024 earnings released: EPS: ₹0.63 (vs ₹0.15 in 3Q 2023)

Investor sentiment improves as stock rises 17%

Morepen Laboratories Limited to Report Nine Months, 2024 Results on Jan 31, 2024

Morepen Laboratories Limited Announces Resignation of Rolli Saxena, General Manager - HR, Being A Functional Head and Senior Management Personnel

Investor sentiment improves as stock rises 17%

Morepen Laboratories (NSE:MOREPENLAB) Seems To Use Debt Quite Sensibly

Second quarter 2024 earnings released: EPS: ₹0.42 (vs ₹0.33 in 2Q 2023)

Morepen Laboratories Limited to Report Q2, 2024 Results on Nov 02, 2023

Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)

Morepen Laboratories Limited, Annual General Meeting, Sep 28, 2023

Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?

First quarter 2024 earnings released: EPS: ₹0.29 (vs ₹0.12 in 1Q 2023)

Full year 2023 earnings released: EPS: ₹0.77 (vs ₹2.26 in FY 2022)

Morepen Laboratories Limited to Report Q4, 2023 Results on May 16, 2023

Third quarter 2023 earnings released: EPS: ₹0.15 (vs ₹0.48 in 3Q 2022)

Morepen Laboratories Limited to Report Q3, 2023 Results on Feb 13, 2023

Investor sentiment improved over the past week

Insufficient new directors

Second quarter 2023 earnings released: EPS: ₹0.33 (vs ₹0.83 in 2Q 2022)

Morepen Laboratories Limited to Report Q2, 2023 Results on Nov 10, 2022

Investor sentiment deteriorated over the past week

Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)

Morepen Laboratories Limited, Annual General Meeting, Sep 27, 2022

Insufficient new directors

First quarter 2023 earnings released: EPS: ₹0.12 (vs ₹0.68 in 1Q 2022)

Morepen Laboratories Limited to Report Q1, 2023 Results on Jul 29, 2022

Morepen Laboratories Limited Announces Resignation of Anju Suri as Director (Non-Executive, Non-Independent)

Morepen Laboratories Limited announced that it has received INR 1.1465201 billion in funding from a group of investors

Full year 2022 earnings released: EPS: ₹2.26 (vs ₹2.16 in FY 2021)

Investor sentiment improved over the past week

Should You Be Adding Morepen Laboratories (NSE:MOREPENLAB) To Your Watchlist Today?

Investor sentiment improved over the past week

Morepen Laboratories Limited Announces Cessation of Arun Kumar Sinha as Whole Time Director

Morepen Laboratories Limited announced that it expects to receive INR 1.1465201 billion in funding from a group of investors

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2022 earnings released: EPS ₹0.83 (vs ₹0.60 in 2Q 2021)

Less than half of directors are independent

Do Morepen Laboratories's (NSE:MOREPENLAB) Earnings Warrant Your Attention?

Investor sentiment improved over the past week

Less than half of directors are independent

Investor sentiment deteriorated over the past week

First quarter 2022 earnings released: EPS ₹0.68 (vs ₹0.43 in 1Q 2021)

Investor sentiment improved over the past week

Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?

Morepen Laboratories Limited announced that it expects to receive INR 4.3336 billion in funding from Liquid Holdings Pvt Ltd, Corinth Investment Holdings AG

Investor sentiment improved over the past week